Retaglutide and tirzepatide are newer GLP-1 receptor agonists gaining attention as effective treatment options for type 2 diabetes. These medications enhance insulin secretion from the pancreas, suppress glucagon release, and delay gastric glp-2 emptying, leading to improved glycemic control. Retaglutide is administered subcutaneously, while tirzep